EFFECTS OF DOSE, PH AND OSMOLARITY ON INTRANASAL ABSORPTION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN RATS

被引：0

作者：

SHIMODA, N ^{[1
]}

MAITANI, Y ^{[1
]}

MACHIDA, Y ^{[1
]}

NAGAI, T ^{[1
]}

机构：

[1] CHUGAI PHARMACEUT CO LTD, DEPT BUSINESS COORDINAT, DIV DEV & TECHNOL, KITA KU, TOKYO 115, JAPAN

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 1995年 / 18卷 / 05期

关键词：

ERYTHROPOIETIN; INTRANASAL ADMINISTRATION; GLYCOPROTEIN CIRCULATING RETICULOCYTE; BIOAVAILABILITY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of dose, pH and osmolarity on the intranasal absorption of a recombinant human erythropoietin (rEPO) solution were studied in male Wistar rats, The intranasal administration of rEPO was evaluated by measuring percentage circulating reticulocytes of red blood cells on a stained blood smear (smear method), and also by measuring residual circulating reticulocyte counts using a microcell counter (sysmex method), Both results suggest that rEPO solution was absorbed through the nasal mucosa of rats without enhancers after a single intranasal administration, The pharmacological availabilities of rEPO after intranasal administration compared with intravenous administration were about 7% and 4%, when estimated by smear method and sysmex method, respectively, The pharmacological activity was enhanced in low pH and hypotonic mannitol solution.

引用

页码：734 / 739

页数：6

共 50 条

[31] HIGH-DOSE RECOMBINANT-HUMAN-ERYTHROPOIETIN ADMINISTERED INTRAVENOUSLY FOR THE TREATMENT OF ANEMIA IN MYELODYSPLASTIC SYNDROMES [J].

CASADEVALL, N ;

BELANGER, C ;

GOY, A ;

VARET, B ;

LANG, J ;

POISSON, D .

ACTA HAEMATOLOGICA, 1992, 87 :25-27

[32] ERYTHROPOIETIN DEFICIENCY - A COMPLICATION OF CISPLATIN THERAPY AND ITS TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].

BRAY, GL ;

REAMAN, GH .

AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1991, 13 (04) :426-430

[33] EARLY TREATMENT OF PREMATURE-INFANTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].

MESSER, J ;

HADDAD, J ;

DONATO, L ;

ASTRUC, D ;

MATIS, J .

PEDIATRICS, 1993, 92 (04) :519-523

[34] IMPROVED SEXUAL FUNCTION DURING RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY [J].

BOMMER, J ;

KUGEL, M ;

SCHWOBEL, B ;

RITZ, E ;

BARTH, HP ;

SEELIG, R .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1990, 5 (03) :204-207

[35] INHIBITORS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CHRONIC-RENAL-FAILURE [J].

VANDULLEMEN, HM ;

LUYKXDEBAKKER, S ;

HILLEN, PH ;

VANLANDEGHEM, AAJ ;

VANBOVEN, WPL ;

VANDERHEUL, C .

NETHERLANDS JOURNAL OF MEDICINE, 1992, 41 (1-2) :56-63

[36] STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ANALOGS [J].

BITTORF, T ;

JASTER, R ;

BROCK, J .

FEBS LETTERS, 1993, 336 (01) :133-136

[37] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HOSPITALIZATION OF HEMODIALYSIS-PATIENTS [J].

CHURCHILL, DN ;

MUIRHEAD, N ;

GOLDSTEIN, M ;

POSEN, G ;

FAY, WF ;

BEECROFT, ML ;

GORMAN, J ;

TYLOR, DW .

CLINICAL NEPHROLOGY, 1995, 43 (03) :184-188

[38] DETERMINATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN BY SQUARE-WAVE VOLTAMMETRY [J].

HERNANDEZ, P ;

NIETO, O ;

HERNANDEZ, L .

ANALYTICA CHIMICA ACTA, 1995, 305 (1-3) :340-346

[39] RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE TREATMENT OF CANCER-RELATED ANEMIA [J].

FALKSON, CI ;

KERENROSENBERG, S ;

UYS, A ;

FALKSON, G ;

STEVENS, K ;

VERMAAK, WJH .

ONCOLOGY, 1994, 51 (06) :497-501

[40] SUBCUTANEOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR THE TREATMENT OF ANEMIA IN MYELODYSPLASTIC SYNDROMES [J].

GHIO, R ;

BALLEARI, E ;

BALLESTRERO, A ;

GATTI, AM ;

MARENI, C ;

MASSA, G ;

PATRONE, F ;

SESSAREGO, M ;

TIMITILLI, S .

ACTA HAEMATOLOGICA, 1993, 90 (02) :58-64

← 1 2 3 4 5 →